2008 Press Releases
TSX:V - IXS
NASD OTC:BB: IXSBF
May 7, 2008
InNexus Biotechnology Launches Competitive Summer Intern Program -- LABapprentice --
BRITISH COLUMBIA, Canada-15 April 2008-InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS), (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™), begins LABapprentice, a competitive summer intern program with a twist, to reach internet surfers via the website: www.labapprentice.com.
The producers of LABapprentice say viewers are in for an adventure with its weekly lab challenges and a panel of scientific and corporate leaders whose demands are high for the eight thrill-seeking interns. Beware this action packed series is sure to be a hit and a wonderful way to view the inner-workings of a biotechnology company.
Jeff Morhet, Committee Panel Member and InNexus Chairman & CEO said, "Admission into the LABapprentice program will be competitive, but many different backgrounds and abilities will be represented among the students selected. Interns may look forward to a challenging, but rewarding experience working side-by-side with scientists developing the next generation of cancer drugs."
Check out the first episode spotlighted via www.labapprentice.com where viewers will be able to ‘surf in’ via the website each week and watch the progress of the Interns. Be sure to visit in the coming weeks and see profiles on the Interns and learn about their challenges and path to becoming The Next LABapprentice.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of The Mayo Clinic and has its own in–house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward–looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Contact:
Jeff Morhet, Chairman & Chief Executive Officer
Dr. Thomas Kindt, Chief Scientific Officer
InNexus Biotechnology Inc.
480-862-7500
www.ixsbio.com
